Asparaginase

Also known as: Colaspase

Active ingredient description

Asparaginase hydrolyses asparagine to aspartic acid and ammonia. In contrast to normal cells, lymphoblastic tumour cells have a very limited capacity for synthesising asparagine because of a significantly reduced expression of asparagine synthetase. Therefore, they require asparagine which diffuses from the extracellular environment. As a result of asparaginase-induced asparagine depletion in serum, protein synthesis in lymphoblastic tumour cells is disturbed while sparing most normal cells.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Asparaginase
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX02

Medicines

Asparaginase is the active ingredient of these drugs:

Drug
Countries

Austria Canada Netherlands Poland United Kingdom

United States

Canada France

South Africa

Hong Kong Singapore

Austria Brazil France Ireland Lithuania

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country

Unique ingredient identifier (UNII)

G4FQ3CKY5R - ASPARAGINASE

CAS registry number

9015-68-3 - Asparaginase

SNOMED-CT

18780003 - Asparaginase (substance)

371014004 - Asparaginase (substance)